Paper3545116
Comparison of ketanserin and metoprolol in the treatment of essential hypertension.
Sheps SG and 7 others. Arch Intern Med, 1987. Cited by 21 papers, by iCite.
Cite this record
ConductScience Library. Comparison of ketanserin and metoprolol in the treatment of essential hypertension. Papers, record 3545116. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3545116
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Publication types
- Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Hypertension | Major topic |
| Ketanserin | Major topic |
| Metoprolol | Major topic |
| Blood Pressure | |
| Clinical Trials as Topic | |
| Female | |
| Heart Rate | |
| Humans | |
| Male | |
| Middle Aged | |
| Posture | |
| Time Factors |
Source PubMed
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 21 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41621142 | Specific serotonin receptor antagonist reduces murine calcific atherosclerosis. | Atherosclerosis | 2026 | https://conductscience.org/library/papers/41621142 | PubMed |
| 39658346 | β-Blockers and risk of neuropsychiatric disorders: A systematic review and meta-analysis. | Br J Clin Pharmacol | 2025 | https://conductscience.org/library/papers/39658346 | PubMed |
| 3240729 | Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin. | Drugs | 1988 | https://conductscience.org/library/papers/3240729 | PubMed |
| 3071461 | Ketanserin in the treatment of diabetes-associated hypertension. | Drugs | 1988 | https://conductscience.org/library/papers/3071461 | PubMed |
| 2467792 | Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin. | Drugs | 1988 | https://conductscience.org/library/papers/2467792 | PubMed |
| 2079001 | Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. | Drugs | 1990 | https://conductscience.org/library/papers/2079001 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| REN | 5972 | PubTator's text mining | https://conductscience.org/library/genes/5972 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3545116
GET https://conductscience.org/api/papers/v1/3545116/authors